Corvus Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, has announced that it has entered into a strategic collaboration with Angel Pharmaceuticals that will enable the development and commercialization of its pipeline of precisely targeted investigational medicines in China.

Latham & Watkins LLP represents Corvus Pharmaceuticals, Inc. in the transaction. The healthcare and life sciences team was led by Bay Area partner Judith Hasko, with Bay Area associates Jekkie Kim and Katie Mladinich and New York associate Jiqiang Lin. The corporate team was led by Shanghai partner Rowland Cheng, with Shanghai associate Vincent Jiang. Bay Area partners Alan C. Mendelson and Miles Jennings also advised with respect to corporate and securities matters.

In addition, Advice was provided on tax matters by Bay Area partner Kirt Switzer, with Bay Area associate Jessica Chen.